Monoclonal antibodies against programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) are effective therapies in patients with non-small cell lung cancer (NSCLC). Herein, the authors performed a systematic review investigating differences in the toxicities of PD-1 and PD-L1 inhibitors. METHODS: An electronic literature search was performed of public databases (MEDLINE, Excerpta Medica dataBASE [EMBASE], and Cochrane) and conference proceedings for trials using PD-1 inhibitors (nivolumab and pembrolizumab) and PD-L1 inhibitors (atezolizumab, durvalumab, and avelumab) in patients with NSCLC. A formal systematic analysis was conducted with Comprehensive Meta-Analysis software (version 2.2). Clinical and demographic characteristics, response, and toxicity data were compared between both groups. RESULTS: A total of 23 studies reported between 2013 and 2016 were eligible for analysis. The total number of patients evaluated for toxicities was 3284 patients in the PD-1 group and 2460 patients in the PD-L1 group. The baseline patient characteristics of the 2 groups were similar, although there was a trend toward increased squamous histology in the group treated with PD-L1 (32% vs 25%; P 5 .6). There was no difference in response rate noted between PD-1 (19%) and PD-L1 (18.6%) inhibitors (P 5 .17). The incidence of overall adverse events (AEs) was comparable between the PD-1 and PD-L1 inhibitors (64% [95% confidence interval (95% CI), 63%-66%] vs 66% [95% CI, 65%-69%]; P 5 .8). Fatigue was the most frequently reported AE with both classes of drugs. Patients treated with PD-1 inhibitors were found to have a slightly increased rate of immune-related AEs (16% [95% CI, 14%-17%] vs 11% [95% CI, 10%-13%]; P 5 .07) and pneumonitis (4% [95% CI, 3%-5%] vs 2% [95% CI, 1%-3%]; P 5 .01) compared with patients who received PD-L1 inhibitors. CONCLUSIONS: In this systematic review involving 5744 patients with NSCLC, the toxicity and efficacy profiles of PD-1 and PD-L1 inhibitors appear to be similar. Cancer 2018;124:271-7.
INTRODUCTION
Immune checkpoint inhibition is an effective treatment strategy in multiple tumor types, including non-small cell lung cancer (NSCLC). The immune checkpoint programmed cell death protein 1 (PD-1) receptor is expressed on activated T cells and binds to its ligands PD-L1 and PD-L2 to limit T-cell activation and prevent autoimmunity in peripheral tissues. 1 Activation of the PD-1 pathway induces T-cell exhaustion, which is necessary to prevent continued immune activation after the successful removal of cells carrying the antigen of interest. 2 Several tumors overexpress PD-L1 and evade detection by T cells, which leads to immune tolerance of the tumor. Overexpression of PD-L1 also is associated with more aggressive phenotypes and poor outcomes in patients with NSCLC.
The immune checkpoint inhibitors have unique mechanism-based toxicities compared with cytotoxic chemotherapy. Inhibition of the PD-1 pathway can lead to autoimmune toxicities, some of which can be severe, and even fatal reactions. 13, 14 Patients with lung cancer in particular are more vulnerable to toxicities given the older age of the patient population and the presence of comorbid conditions. Of particular interest in patients with NSCLC is the development of autoimmune pneumonitis, which has led to a few treatment-related deaths in early-phase studies of these agents. [15] [16] [17] Because clinicians have increasing numbers of checkpoint inhibitors to choose from in the treatment of patients with advanced stage NSCLC, it will be important to understand potential differences in the efficacy and toxicity profiles of these agents. There has been speculation that because monoclonal antibodies against PD-L1 still allow for the interaction of PD-1 with its other ligand, PD-L2, this could lead to less blockade of the negative inhibitory signal and result in reduced autoimmunity. To the best of our knowledge, the question of whether this also has implications for the efficacy of the individual agents is not known. Given that it is highly unlikely that comparative clinical trials will be conducted to compare the checkpoint inhibitors against one another, there is an urgent need to understand key differences in efficacy and toxicity between the various immune checkpoint inhibitors. In particular, comparison of PD-1 versus PD-L1 inhibitors is of immense clinical interest. Therefore, we conducted a systematic review of clinical trials to evaluate differences in toxicity profiles between PD-1 and PD-L1 inhibitors used as monotherapy for patients with NSCLC.
MATERIALS AND METHODS

Search Strategy
A comprehensive and methodical search of the literature of electronic databases (Medline, Excerpta Medica data-BASE [EMBASE], and Cochrane) for studies published between 2000 and 2016 was conducted. Applicable terms, such as "PD-1," "PD-L1," and "NSCLC," were used with the filters "clinical trial," "humans," and "all adult: 191 years" for the MEDLINE searches. Relevant abstracts were manually searched and retrieved from the conference proceedings of annual meetings of the American Society of Clinical Oncology (2011-2016), the International Association for the Study of Lung Cancer World Conference on Lung Cancer (2011) (2012) (2013) (2014) (2015) (2016) , and the European Society for Medical Oncology (2011-2016).
Study Eligibility
All studies potentially meeting the eligibility criteria defined by the search strategy were independently reviewed by 3 of the authors (R.N.P., M.B., and S.S.R.), which was followed by a consensus meeting to determine the final list of eligible studies. All trials using PD-1 inhibitors (nivolumab and pembrolizumab) and PD-L1 inhibitors (atezolizumab, durvalumab, and avelumab) as monotherapy in patients with NSCLC were included in the current analysis. Phase 1 trials; trials that enrolled <10 patients; and trials that used PD-1 or PD-L1 inhibitors in combination with chemotherapy, other immunotherapies, or radiotherapy were excluded from the current analysis, as were studies that did not report toxicities. For data that were both presented at a meeting and subsequently published in full form, only those data from the full publication were included. If data had been presented multiple times, then the data from the most current presentation were used, and the older data were excluded. All prospective randomized, nonrandomized, and single-arm studies that met the inclusion criteria were included in the analysis. Retrospective studies were excluded from this analysis.
Data Extraction and Statistical Analysis
The studies were reviewed for any available data. Standard data extraction templates were used to collect any analyzable data that were reported. The extracted data included demographics, treatment, and clinical outcomes including overall response rate, progression-free survival, overall survival, and toxicities. Not all of the trials reported all outcome measures. Toxicities were extracted as the primary outcome for the current analysis.
The outcome data extracted for each arm were analyzed using the fixed effects model, which controls for timeinvariant variables and reports them as weighted measures. Each study in the fixed effect analysis is weighted based on its sample size. Toxicities were extracted and reported as overall adverse events (AEs), grade 3 to 5 AEs, most common AEs, and immune-related AEs (IRAEs). Toxicities and their severity were reported by each study using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3 or version 4. Depending IRAEs were defined as toxicities mediated by an autoimmune mechanism, defined by us to include pneumonitis, colitis, thyroid disorders, and inflammatory conditions reported in any organ system (eg, hepatitis or nephritis). All analyses were performed using Comprehensive MetaAnalysis software (version 2.2; Biostat Inc, Englewood, New Jersey) and SPSS statistical software (version 22.0; IBM Corporation, Armonk, New York). The comparisons between the 2 arms of PD-1 and PD-L1 inhibitors were conducted based on weighted estimates. A 2-tailed Student t test with a significance level of .05 was used for all comparisons. Heterogeneity among studies was assessed used the I 2 test, which provides the percentage of variation across studies that is due to the heterogeneity. The overall AE rate was reported as pooled proportions of the percentage of patients treated with each drug who experienced AEs; there was no test of significance performed between the drugs.
RESULTS
A total of 549 studies were retrieved and reviewed from the searches, 23 of which met the inclusion criteria of the current study. Of these, 12 trials used PD-1 inhibitors and 11 trials used PD-L1 inhibitors. The study selection scheme is shown in Figure 1 . The trials with PD-1 inhibitors and PD-L1 inhibitors that met the current study criteria and were included in the current analysis are outlined in Table 1 . [8] [9] [10] [11] [12] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] A total of 5744 patients were evaluated for toxicity, including 3284 patients who were treated with PD-1 and 2460 patients who were treated with PD-L1 inhibitors. The patient characteristics are described in Table 2 . The median age of the patients treated with PD-1 inhibitors was 64 years and that of the patients treated with PD-L1 inhibitors was 64.5 years (P 5 .5). The patients treated with PD-1 inhibitors had a slightly higher percentage of men compared with the population treated with PD-L1 inhibitors (59% vs 56%; P 5 .4). The 2 cohorts had a similar percentage of patients with a history of smoking (83%; P 5 .5). Although the 2 cohorts were comparable with regard to baseline characteristics, trials using PD-L1 enrolled a higher percentage of patients with squamous histology compared with the PD-1 trials (32% vs 25%; P 5 .6).
The overall response rate in the population treated with PD-1 inhibitors (3284 patients) was identical to that of the group treated with PD-L1 inhibitors (2460 patients) (19% vs 18.6%; P 5 .17) ( Table 3 ). The progression-free survival and overall survival data were only reported in a few studies, and were not sufficient to make a comparable analysis.
Toxicities
The overall incidence of AEs was found to be similar between the cohorts treated with PD-L1 and PD-1 inhibitors (Table 3) , with patients treated with PD-1 inhibitors experiencing a comparable incidence of AEs compared with those receiving PD-L1 inhibitors (64% in the PD-1 inhibitor group [95% confidence interval [95% CI], 63%-66%] vs 66% in the PD-L1 inhibitor group [95% CI, 65%-69%]; P 5 0.8). Grade 3 to 5 toxicities were observed in 13% of the PD-1 cohort (95% CI, 12%-14%) versus 21% of the PD-L1 cohort (95% CI, 19%-23%) (P 5.15). Fatigue was the most common toxicity reported in both cohorts of patients (19% in patients treated with PD-1 inhibitors [95% CI, 17%-20%] vs 21% in the patients treated with PD-L1 inhibitors [95% CI, 19%-23%]; P 5 .4). The overall rate of IRAEs had a trend toward a higher incidence with PD-1 inhibitors compared with PD-L1 inhibitors (16% [95% CI, 14%-17%] vs 11% [95% CI, 10%-13%]; P 5 .07) ( Table 3) , although the rate of grade 3 to 5 IRAEs was found to be equivalent in the 2 groups (3%; P 5 .4). The most common IRAE was hypothyroidism in both groups. Although the incidence of hypothyroidism was numerically higher with PD-1 inhibitors compared with PD-L1 inhibitors, this difference was not statistically significant (6.7% in the PD-1 inhibitor cohort [95% CI, 6%-8%] vs 4.2% in the PD-L1 inhibitor cohort [95% CI, 3%-5%]; P 5 .07). The incidence of pneumonitis was higher in the patients treated with PD-1 inhibitors versus those receiving PD-L1 inhibitors (4% [95% CI, 3%-5%] vs 2% [95% CI, 1%-3%]; P 5 .01). When the incidence of toxicities was analyzed by the type of drug, durvalumab was found to be associated with the highest percentage of toxicities (Table 4) .
DISCUSSION
Immune checkpoint inhibition with PD-1 and PD-L1 inhibitors has become a standard of care for patients with metastatic NSCLC. Although each drug has activity in NSCLC, to the best of our knowledge it is unclear how these agents compare in terms of efficacy and toxicity. Our systematic review of 5744 patients with NSCLC who were treated with PD-1 and PD-L1 inhibitors sheds light on this important clinical issue, and provides guidance for treating physicians and researchers. The objective response rate appears to be similar for PD-1 and PD-L1 inhibitors in an unselected population with advanced stage NSCLC. The toxicity profiles also appear to be comparable between the 2 classes of checkpoint inhibitors, with relatively minor differences. First, the overall incidence of clinically significant AEs was low with immune checkpoint inhibition, which represents a significant improvement in the therapeutic index compared with systemic chemotherapy. Fatigue was the most common AE noted with both PD-1 and PD-L1 inhibitors. Even among IRAEs, the differences between the 2 classes of agents were relatively minor. In our view, the most notable difference was observed for grades 3/4 immune-mediated pneumonitis, which was slightly Original Article higher with PD-1 inhibitors compared with PD-L1 inhibitors.
The current study used a large data set and to the best of our knowledge is the first systematic review to date of toxicity profiles of immune checkpoint inhibitors in patients with NSCLC. This analysis adds to the understanding of differences between PD-1 and PD-L1 inhibitors in patients with NSCLC. A major strength of the current study is that several of the trials included were conducted in the multinational setting, and therefore are representative of a heterogeneous and representative patient population from across the world. This included a phase IIIB/IV safety study, the CheckMate 153 study, which collected data regarding patients with advanced NSCLC who were treated with nivolumab in community oncology practices. 20 The results of this study demonstrated that checkpoint inhibitor therapy with nivolumab was well tolerated, even in patients with a performance status of 2, with a rate of treatment-related AEs of 53%, and reflects a more real-world practice setting. The majority of these studies enrolled patients primarily from North America and Europe, although we did identify phase 2 data from Sakai et al that reported on the use of nivolumab in 111 patients in Japan. 19 Based on this report, the efficacy and toxicity in Japanese patients appears to be similar to that of the overall population of patients analyzed. Asia is the only region that was not represented proportionally, and hence it will be important to study this issue as more trials are specifically conducted in Asia.
There are limitations to the current study despite the comprehensive nature of our review. We selected the toxicity data by using reported treatment-related AEs whenever possible. However, not all the studies had toxicity reported as a treatment-related AE. In addition, the attribution of an AE as related to treatment could be somewhat subjective and vary between clinical trials and drugs.
Another caveat of the current analysis is the availability of toxicity data. When possible, we used full publications to extract toxicity data for each clinical trial. Some of the newer data were available only as presentations from conferences. In these cases, there were limited toxicity data available for extraction. This could lead to a selection bias of more toxicity reporting in the studies with more complete AE data in the full publication. It is interesting to note that because the PD-1 inhibitors have been in clinical development longer, more of the studies of these agents were available in full publication format. A higher percentage of studies regarding PD-L1 inhibitors were reported only at conferences and this could explain some of the differences in toxicities observed between the PD-1 and PD-L1 inhibitors.
The most significant finding of the current study was the doubling in the rate of pneumonitis noted among patients treated with PD-1 inhibitors. Again, this may have been due in part to less complete AE reporting with the PD-L1 inhibitors; these drugs are in earlier phases of clinical development and also have fewer complete publications available for review. The rate of pneumonitis could have been influenced by the different inclusion criteria used in each study with regard to allowing patients with prior interstitial lung diseases. We did not have access to the inclusion criteria for all of the clinical trials included in the current analysis. Another potential confounding factor contributing to the difference in pneumonitis incidence could be the underreporting of pneumonitis as other toxicities, such as pneumonia, dyspnea, or interstitial lung disease.
We also acknowledge that the current meta-analysis was not based on individual patient data, which would have been an ideal way to study this issue. A meta-analysis of individual patient data would have been more comprehensive and would have allowed for better time-totoxicity assessment. However, given that the trials were conducted primarily by the respective pharmaceutical companies, gaining access to primary data sets is challenging.
The comparison of efficacy in terms of response rate in the current study was a secondary and exploratory endpoint and also has limitations. The patients included herein were from clinical trials in different phases of drug development. There also was variability with regard to the number of treatment lines received. Furthermore, some of the patients enrolled in these studies were selected based on PD-L1 expression. There is a reported association between a higher likelihood of response and tumor expression of PD-L1, 34 and the heterogeneity of PD-L1 expression in these patients also could have impacted the reported overall response rate and toxicities.
Despite these limitations, we believe the current systematic review adds to our knowledge of the toxicity profiles and efficacy of PD-1 and PD-L1 inhibitors in patients with NSCLC. It will be interesting to learn how information changes with more frontline data and combination strategies being reported. Because to the best of our knowledge these studies are among the first to evaluate this entirely new class of anticancer agents, it is likely that the steep learning curve for the early recognition and management of toxicities with more clinical experience will result in an even more favorable toxicity profile for Another important way to improve the risk-benefit ratio is to choose treatment based on biomarkers, which currently is an area of active investigation. PD-L1 expression in tumor tissue has emerged as a valuable selection method, although it is subject to certain limitations. Currently, the cost of PD-1 and PD-L1 inhibitors also are similar in the United States, and hence treatment choice will be based primarily on proven efficacy in the chosen setting and the schedule of administration.
PD-1 and PD-L1 inhibitors both appear to be associated with comparable efficacy and toxicity in patients with advanced stage NSCLC.
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